Featured Press Release

  • 8/28/19 4:30 pm EDT
    WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the Morgan Stanley 17th Annual Global Healthcare Conference as follows:   Date: Wednesday, September 11, 2019 Time: 9:20 a.m. Eastern Daylight Time Location: Grand Hyatt New York, NYC Webcast: https://cc.talkpoint.com/morg007/See More
  • 8/8/19 6:50 am EDT

    -- Q2 2019 net income of $0.49 per basic and $0.48 per diluted share and adjusted non-GAAP net income of $0.86 per basic and $0.84 per diluted share --

    -- Announced clinical development plan for its innovative fulvestrant program intended to deliver maximum estrogen receptor inhibition in patients with estrogen receptor (ER)-positive breast cancer --

    -- Pipeline programs advancing on track; Eagle reiterating R&D expense guidance --

    WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced its financial results for the three- and six-months ended June 30, 2019. Highlights of, and subsequent to, the second quarter of 2019 include: Business and Financial Highlights: On August 5, 2019, Eagle announced a clinical development plan, following guidance from the U.S. Food and Drug Administration (FDA), for its fulvestrant formulation, intended to deliverSee More
  • 8/5/19 6:50 am EDT

    -- Eagle plans to conduct a Pilot Study shortly followed by a Pivotal Trial --

    -- Pivotal Trial expected to be completed within approximately 12 months of commencing enrollment --

    WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced a clinical development plan to support the submission of a New Drug Application (NDA) for the Company’s innovative fulvestrant formulation. Fulvestrant, an estrogen receptor antagonist with no agonist properties, is approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced hormone-related breast cancers. The therapeutic effect of fulvestrantSee More
Business Wire InvestorHQsm